+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery

A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery

Archives of Orthopaedic and Trauma Surgery 127(8): 665-670

Bemiparin has shown to be effective and safe in clinical trials in total knee or hip replacement. We conducted a prospective, open, multicentre, uncontrolled study to audit the utilisation patterns of bemiparin 3,500 IU/day, first dose administered 6 h after surgery, in 1,009 patients undergoing total hip or knee replacement surgery in standard clinical practice. We analysed rates of documented symptomatic venous thromboembolism (VTE) [deep-vein thrombosis (DVT) and pulmonary embolism (PE)] confirmed by objective methods, major bleeding, death, thrombocytopaenia and other adverse events up to 6 weeks. Rate of documented symptomatic DVT was 0.3% (95% CI, 0.1-0.9%). No cases of documented PE were reported. There were 14 (1.4%) major bleedings (95% CI, 0.8-2.3%). Neuraxial anaesthesia was used in 937 (92.9%) patients. There were no cases of spinal haematoma, fatal bleeding or bleeding in critical organs. There were 6 (0.6%) cases of mild thrombocytopaenia, which did not require treatment discontinuation. No cases of severe type II heparin-induced thrombocytopaenia were observed. There were no deaths during bemiparin prophylaxis. The median length of hospitalisation was 9 days and 92.5% of patients continued prophylaxis post-hospitalisation for a total median time of 38 days. There were no thromboembolic or bleeding complications during post-hospitalisation prophylaxis. Postoperative start of prophylaxis with bemiparin permitted that 29.3% of patients could be admitted to hospital the same day of the intervention. Bemiparin prophylaxis, started 6 h after surgery and given for 5-6 weeks after total hip or knee replacement, was associated with low rates of VTE, major bleeding and other adverse events in normal clinical practice. Bemiparin thromboprophylaxis started 6 h after surgery makes neuraxial anaesthesia/analgesia procedures easier, without compromising efficacy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 048105120

Download citation: RISBibTeXText

PMID: 17089172

DOI: 10.1007/s00402-006-0239-x

Related references

A prospective observational study of falling before and after knee replacement surgery. Age and Ageing 38(2): 175-181, 2008

Effectiveness and safety of different duration of thromboprophylaxis in 16,865 hip replacement patients--a real-word, prospective observational study. Thrombosis Research 135(2): 322-328, 2015

Low dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study. Thrombosis Journal 13: 32, 2015

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery. Pharmacoeconomics 22(13): 885-894, 2004

Incidence, risk factors and the healthcare cost of falls postdischarge after elective total hip and total knee replacement surgery: protocol for a prospective observational cohort study. Bmj Open 6(7): E011139, 2017

A prospective, observational study of the effectiveness, safety and impact on quality of life (QoL) of a weekly fixed dose of darbepoetin alfa (DA) for the treatment of chemotherapy-induced anemia (CIA) in patients (pts) with non-myeloid malignancies. Journal of Clinical Oncology 24(18_suppl): 18588-18588, 2016

Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery. Pharmacy World and Science 24(3): 87-94, 2002

Predicting total knee replacement pain: a prospective, observational study. Clinical Orthopaedics and Related Research 2003(416): 27-36, 2003

Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice. American Journal of Cardiovascular Drugs 17(5): 391-398, 2017

Obesity and the Relative Risk of Knee Replacement Surgery in Patients With Knee Osteoarthritis: A Prospective Cohort Study. Arthritis and Rheumatology 68(4): 817-825, 2016

Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thrombosis and Haemostasis 77(1): 32-38, 1997

Physical activity levels after hip and knee joint replacement surgery: an observational study. Clinical Rheumatology 2018, 2018

Effect of prophylactic treatment with low-molecular-weight heparin bemiparin sodium on serum potassium levels: a prospective observational study. Drugs and Aging 27(5): 399-406, 2010

Effects of anaesthesia and analgesia on long-term outcome after total knee replacement: A prospective, observational, multicentre study. European Journal of Anaesthesiology 34(10): 665-672, 2017

Increased risk for knee replacement surgery after arthroscopic surgery for degenerative meniscal tears: a multi-center longitudinal observational study using data from the osteoarthritis initiative. Osteoarthritis and Cartilage 25(1): 23-29, 2016